30. October 2009 09:24
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
The presentation details are as follows: Date / Time: Tuesday November 3, 2009 4:20 pm ET Location: InterContinental Hotel, Boston, MA Track: Targeting
Diabetes with Novel Therapeutics - Strategically Advancing Clinical Compounds Title: Liver Directed Beta Agonist for Targeting Cardio- metabolic Disease
In addition, Dr. Taub will participate in other forums on Wednesday November 4, 2009, including a panel on the "Clinical Landscape for New Diabetes Drug Candidates".
SOURCE VIA Pharmaceuticals, Inc.
dc3e11a9-733c-4c48-b4a8-fee8ef8f3d97|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Atherosclerosis, Biotechnology, Cardiovascular Disease, Cholesterol, Diabetes, Dyslipidemia, Hypercholesterolemia, Insulin, Metabolism, Obesity, Stroke, Triglyceride, Type 2 Diabetes, Weight Loss
Subscribe